HomeEarly Access ProgramsProgram Strategy & Design

Early Access Programs

Program Strategy
& Design.

Successful strategies.

The EAP space is ever-evolving, and pressures on pharma companies to provide early access to their promising treatments is greater than ever. This brings opportunities and risks that need to be well thought through and planned for.

We have convened a team of leaders in the industry with unrivalled experience in the successful implementation of global EAPs. As a result, we are able to advise and guide our clients in order that a sound strategy can be created and successfully implemented.

Whether you are in very early stages of development or ready to provide access to an investigational treatment during Phase II, Phase III, post-trial or beyond; the Bionical Emas EAP team can provide the solutions.

Case studies.

Global EAP for a specialised Biotech company Play Video
European EAP with tailored RWD strategy Play Video
Global early access program takeover Play Video

How can we support you?

If you are a Healthcare Professional seeking access to a Bionical Emas EAP product

COVID-19 Guidance & Measures

A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.